Skip to main content
Clinical Trials/NCT05887479
NCT05887479
Withdrawn
Phase 4

The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity

Sisli Hamidiye Etfal Training and Research Hospital0 sitesMay 25, 2023

Overview

Phase
Phase 4
Intervention
Botulinum toxin type A
Conditions
Cerebrovascular Disorders
Sponsor
Sisli Hamidiye Etfal Training and Research Hospital
Primary Endpoint
The Fugl-Meyer assessment scale
Status
Withdrawn
Last Updated
2 years ago

Overview

Brief Summary

The patients between the ages of 35-80 who developed spasticity in the upper extremity after stroke will be included.. Botulinum toxin(BT-A) injection will be applied to the study group(n=16) and placebo injection to the control group(n=15) in addition to conventional rehabilitation and stretching exercises. Evaluations will be made before the treatment, in the 2nd week, and in 3rd month after the treatment. Pain relief will be evaluated with the Visual Analog Scale(VAS) and spasticity assessment will be done with the Modified Ashworth Scale(MAS). The functionality will be evaluated with Fugl Meyer Assessment Scale(FMAS) and Box Block Test(BBT).

Registry
clinicaltrials.gov
Start Date
May 25, 2023
End Date
August 15, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sisli Hamidiye Etfal Training and Research Hospital
Responsible Party
Principal Investigator
Principal Investigator

Aylin Ayyıldız

Medical Doctor

Sisli Hamidiye Etfal Training and Research Hospital

Eligibility Criteria

Inclusion Criteria

  • hemiplegia due to a cerebrovascular accident at least 1 month ago
  • cognitively competent
  • have spasticity of 1 and above according to the Modified Ashworth Scale
  • receive at least 3 cubes in the Box Block Test

Exclusion Criteria

  • Patients with upper extremity brachial plexus lesions,
  • shoulder subluxation,
  • arthritis and joint contracture,
  • neglect syndrome,
  • cerebellar and brain stem lesions
  • those who did not accept the study

Arms & Interventions

Study Group

This is the group that will be injected with botulinum toxin for spasticity and stretching exercises will be given.

Intervention: Botulinum toxin type A

Control Group

This is the group that will be injected with %0,9 NaCl for spasticity and stretching exercises will be given.

Intervention: %0,9 NaCl

Outcomes

Primary Outcomes

The Fugl-Meyer assessment scale

Time Frame: 2 weeks after treatment

The Fugl-Meyer assessment scale (FMAS) will be used to evaluate the motor functions of the upper extremity.

Range of Motion

Time Frame: 2 weeks after treatment

Passive flexion, abduction and external rotation of the shoulder, supination of the elbow, and extension of the wrist will be evaluated by the same physician by goniometry. In addition, elbow, proximal interphalangeal, and distal interphalangeal joints will be evaluated as a limitation of extension.

Modified Ashworth Scale

Time Frame: 2 weeks after treatment

The modified Ashworth Scale (MAS) will be used to evaluate spasticity. The adductor, internal rotator of shoulder, flexor of elbow, wrist and finger, pronator of elbow spasticities will be evaluated using MAS while the patient was in the sitting position.

Pain - Visual Analog Scale

Time Frame: 2 weeks after treatment

The shoulder pain of the patients will be evaluated during passive movement of the shoulder joint. The Visual Analogue Scale (VAS), a score between 0 and 10, will be used in the evaluation.

Secondary Outcomes

  • Pain - Visual Analog Scale(3 months after treatment)
  • Range of Motion(3 months after treatment)
  • Modified Ashworth Scale(3 months after treatment)
  • The Fugl-Meyer assessment scale(3 months after treatment)

Similar Trials